The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
BIO Buyback image

Bio-Rad Laboratories, Inc. Buyback

OLI recorded this information on 11/28/2017

Company: Bio-Rad Laboratories, Inc.
Buyback: BIO buyback
$Amount Authorized: $250,000,000
Buyback Details: Bio-Rad Laboratories, Inc. (NYSE:BIOandBIOb), a global provider of life science research and clinical diagnostic products, today announced that its board of directors has authorized a new share repurchase program, granting the Company authority to repurchase, on a discretionary basis, up to $250 million of the outstanding shares of the Company's common stock.

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. Co. offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Co. operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes.

BIO SEC Filing Email Alerts Service

Open the BIO Page at The Online Investor »

BIO — Key Stats (updated Fri., Apr. 18, 11:01 AM)
Company Name:  Bio-Rad Laboratories Inc
Stock buyback:  BIO buyback
Website:  www.bio-rad.com
Sector:  Biotechnology
Number of ETFs Holding BIO:  126
Total Market Value Held by ETFs:  $888.05M
Total Market Capitalization:  $5.62B
% of Market Cap. Held by ETFs:  15.79%
 

Open the BIO Page at The Online Investor (in a new window) »
April 20, 2025  •  1:52 AM Eastern
BIO — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree BIO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Buy (3.00 out of 4)
27th percentile
(ranked lower than approx. 73% of all stocks covered)

Analysts' Target Price:
BIO Stock Forecast

 Based on Zacks ABR data;
powered by Xignite

BIO Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2025, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.